Fuzionaire Radioisotope Technologies K.K. And Nihon Medi-Physics Enter Feasibility Study Agreement

Fuzionaire Radioisotope Technologies K.K. And Nihon Medi-Physics Enter Feasibility Study Agreement

By, Admin 27 January 2021

Tokyo--(Business Wire)-- Fuzionaire Radioisotope Technologies K.K. (&Ldquo;Frit&Rdquo;) Today Announced That It Has Entered Into A Feasibility Study Agreement With Nihon Medi-Physics Co., Ltd. (&Ldquo;Nmp&Rdquo;), A Leading Radiopharmaceutical Company In Japan, Engaged In R&Amp;D, Manufacturing, And Distribution.Founded In 2019, Frit Is A Joint Venture Between Radiopharmaceutical Companies Fuzionaire Diagnostics, Inc. (&Ldquo;Fuzionaire Dx&Rdquo;) And Japan Medical Isotope Technology Development K.K. To Develop And Commercialize Fuzionaire Dx&Rsquo;S Radiopharmaceutical Technologies In Japan. Founded In 1973, Nmp Is A Joint Venture Between Sumitomo Chemical Company, Limited And Ge Healthcare.Under The Agreement, Nmp Will Evaluate The Ability Of Fuzionaire Dx&Rsquo;S Technology To Create A New Class Of Positron Emission Tomography (Pet) Radiopharmaceuticals. Fuzionaire Dx&Rsquo;S Fluorine-18 Radiolabeling Platform, Powered By A Breakthrough In Fundamental Chemistry Out Of Nobel Prize Winner Robert H. Grubbs&Rsquo; Laboratory At Caltech, Allows The Incorporation Of Fluorine-18 Into A Broad Range Of Ligands At Record-Breaking Speed.One Of Frit&Rsquo;S Priorities Is To Apply This Fluorine-18 Platform To Create New Radiopharmaceuticals That Enable The Prediction And Measurement Of Patient Responses To Cancer Immunotherapy Treatments. In Recent Years, There Have Been Extraordinary Advances In Treatments That Help Patients&Rsquo; Immune Systems Fight Cancer. However, Accurate, Optimized Patient Stratification And Selection Remains A Critical Barrier To Effective Application And Development Of Immunotherapies. Due To The Unique Capabilities Of Positron Emission Tomography &Ndash; Specific, Quantitative, Real-Time, And High-Resolution Imaging Of Markers Of Immunological Response &Ndash; New Pet Radiopharmaceuticals Have The Potential To Remove That Barrier.About Nihon Medi-Physics Co., Ltd.Nihon Medi-Physics Co., Ltd. (Nmp) Is A Leading Company For Radiopharmaceuticals In Japan, Engaged In R&Amp;D, Manufacturing, And Distribution. Nmp&Rsquo;S Stable And Reliable Supply Of Quality Products Has Contributed To Society Over The Years. With Continuous Challenges To New Business Opportunities In The &Ldquo;Development Of Theranostics,&Rdquo; &Ldquo;Application Of Digital Technology In Healthcare&Rdquo; And &Ldquo;Expansion Of Radiopharmaceutical Business In Asia,&Rdquo; Nmp Anticipates To Further Contribute To The Health And Well-Being Of Societies Into The Future.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!